Fatty liver disease

American Liver Foundation Announces Recipients of 2023 Liver Research Awards

Retrieved on: 
Thursday, January 25, 2024
Cirrhosis, Research, Fibrosis, ALF, COVID, Genetics, Liver cancer, Fatty liver disease, Disease, Patient, Liver, Doctor of Philosophy, Biomarker, American Liver Foundation, Lipid metabolism, Liver disease, Dietary supplement

FAIRFIELD, N.J., Jan. 25, 2024 /PRNewswire/ -- Today, the American Liver Foundation (ALF) announced ten new liver research awards that will fund early career scientists working in basic and translational liver disease research. Three researchers will receive a Liver Scholar Award, and seven will receive a Postdoctoral Research Fellowship Award to help advance research in liver biology and disease.

Key Points: 
  • Research topics include fatty liver disease, rare and pediatric liver disease, liver cancer, cirrhosis and more
    FAIRFIELD, N.J., Jan. 25, 2024 /PRNewswire/ -- Today, the American Liver Foundation (ALF) announced ten new liver research awards that will fund early career scientists working in basic and translational liver disease research.
  • Three researchers will receive a Liver Scholar Award , and seven will receive a Postdoctoral Research Fellowship Award to help advance research in liver biology and disease.
  • ALF announces $850,000 in awards to fund early career scientists in basic and translational liver disease research.
  • The 2023 research awards, totaling $850,000 over a three-year period, include research topics such as lipid metabolism, biomarkers, genetics, microbiome immune response, and liver environment, and address important questions in the pathophysiology of fatty liver disease (now called steatotic liver disease), pediatric liver disease , rare liver disease , liver cancer , fibrosis / cirrhosis , and alcohol-associated liver disease .

New Clinical Trial Shows That While The Mediterranean Diet is Good, Pure C15:0 Supplementation Makes It Better

Retrieved on: 
Thursday, January 18, 2024
Fruit, NAFLD, Vegetable, EPA, Health, American Journal, SAN, Diet, Global health, Science, Nut, Fatty liver disease, Insulin, Calorie, LDL, Glucose, Grain boundary strengthening, Liver, Triglyceride, Longevity, Bifidobacterium, Clinical trial, Shellfish, Trial of the century, Blood pressure, Dietary supplement

SAN DIEGO, Jan. 18, 2024 /PRNewswire/ -- A game-changing clinical trial has revealed that enhancing the already renowned Mediterranean diet with pure C15:0 supplementation can elevate health outcomes even further.

Key Points: 
  • In a randomized, double-blinded and controlled clinical trial, supplementation with the same pure C15:0 ingredient in fatty15 improved the health outcomes of the Mediterranean diet.
  • SAN DIEGO, Jan. 18, 2024 /PRNewswire/ -- A game-changing clinical trial has revealed that enhancing the already renowned Mediterranean diet with pure C15:0 supplementation can elevate health outcomes even further.
  • The recent randomized, double-blinded, and controlled clinical trial , published in the American Journal of Clinical Research, has the scientific nutrition community buzzing.
  • Participants were divided into three groups: a caloric-restricted diet, a caloric-restricted diet following Mediterranean diet guidelines, and a caloric-restricted Mediterranean diet with C15:0 supplementation.

Non-Alcoholic Steatohepatitis Treatment Drug Market In Japan is Expected to Showcase Impressive Growth by 2032 | DelveInsight

Retrieved on: 
Wednesday, January 17, 2024
Obesity, Merck & Co., MRI, LAS, Weight loss, Fatty liver disease, Type 2 diabetes, Magnetic resonance imaging, Insulin resistance, NASH, FFAR4, Liver, Liver disease, Diabetes, Alcoholic liver disease, Therapy, Hypertension, PPAR, Eli Lilly and Company, Gilead Sciences, Chronic pain, Disease, Inflammation, FASN, AstraZeneca, Novo Nordisk, FXR, Prevalence, CCR5, FGF, Physical examination, Weakness, Bronchial thermoplasty, Cilofexor, Metabolic syndrome, Mitsubishi Tanabe Pharma, Development, NAFLD, Risk, Fibrosis, Fatigue, Dyslipidemia, USD, Non-alcoholic fatty liver disease, Merck, Pharmaceutical industry

LAS VEGAS, Jan. 17, 2024 /PRNewswire/ -- DelveInsight's Non-Alcoholic Steatohepatitis Market Insights report includes a comprehensive understanding of current treatment practices, non-alcoholic steatohepatitis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into Japan.

Key Points: 
  • LAS VEGAS, Jan. 17, 2024 /PRNewswire/ -- DelveInsight's Non-Alcoholic Steatohepatitis Market Insights report includes a comprehensive understanding of current treatment practices, non-alcoholic steatohepatitis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into Japan.
  • According to DelveInsight's analysis, the market size for NASH reached USD 200 million in 2022 in Japan and is expected to grow with a significant CAGR by 2032.
  • DelveInsight's analysis reveals that the overall diagnosed prevalent population of NASH in Japan was reported as 2.5 million in 2022.
  • Among the forecasted emerging therapies, MGL-3196 (Resmetirom) is expected to capture the highest market in Japan by 2032.

Non-Alcoholic Steatohepatitis Treatment Drug Market In Japan is Expected to Showcase Impressive Growth by 2032 | DelveInsight

Retrieved on: 
Wednesday, January 17, 2024
Obesity, Merck & Co., MRI, LAS, Weight loss, Fatty liver disease, Type 2 diabetes, Magnetic resonance imaging, Insulin resistance, NASH, FFAR4, Liver, Liver disease, Diabetes, Alcoholic liver disease, Therapy, Hypertension, PPAR, Eli Lilly and Company, Gilead Sciences, Chronic pain, Disease, Inflammation, FASN, AstraZeneca, Novo Nordisk, FXR, Prevalence, CCR5, FGF, Physical examination, Weakness, Bronchial thermoplasty, Cilofexor, Metabolic syndrome, Mitsubishi Tanabe Pharma, Development, NAFLD, Risk, Fibrosis, Fatigue, Dyslipidemia, USD, Non-alcoholic fatty liver disease, Merck, Pharmaceutical industry

LAS VEGAS, Jan. 17, 2024 /PRNewswire/ -- DelveInsight's Non-Alcoholic Steatohepatitis Market Insights report includes a comprehensive understanding of current treatment practices, non-alcoholic steatohepatitis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into Japan.

Key Points: 
  • LAS VEGAS, Jan. 17, 2024 /PRNewswire/ -- DelveInsight's Non-Alcoholic Steatohepatitis Market Insights report includes a comprehensive understanding of current treatment practices, non-alcoholic steatohepatitis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into Japan.
  • According to DelveInsight's analysis, the market size for NASH reached USD 200 million in 2022 in Japan and is expected to grow with a significant CAGR by 2032.
  • DelveInsight's analysis reveals that the overall diagnosed prevalent population of NASH in Japan was reported as 2.5 million in 2022.
  • Among the forecasted emerging therapies, MGL-3196 (Resmetirom) is expected to capture the highest market in Japan by 2032.

Inventiva draws down the second tranche of €25 million under existing Finance Contract with the European Investment Bank

Retrieved on: 
Wednesday, January 10, 2024
Patient, Partnership, Finance, Fatty liver disease, Sale, Drug development, Commercial code, EIB, NASH, Exercise, BofA Securities, European Investment Bank, Pharmaceutical industry

The disbursement of the second tranche is expected to occur on or about January 18, 2024.

Key Points: 
  • The disbursement of the second tranche is expected to occur on or about January 18, 2024.
  • On January 4, 2024, and in accordance with the Finance Contract, the Company issued 3,144,654 warrants to EIB.
  • After the drawdown of the first tranche in December 20222, the Company was eligible to access the second tranche of €25 million if it met certain conditions precedent described below.
  • Following the achievement of those conditions, the Company decided to draw on the second tranche to reinforce its financial position.

Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs

Retrieved on: 
Monday, January 8, 2024
Editorial, Diabetes, Risk, CER, Fatty liver disease, Health, Nausea, Tissue, Heart, Cancer, Inflammation, Patent, Ageing, Obesity, Crohn's disease, Liver disease, LEXX, NVO, Invention, DSM-IV codes, Parkinson's disease, Pfizer, Kidney disease, Paratriathlon, European, Disease, Alzheimer's disease, Pharmacokinetics, Bone density, Merck, Facial muscles, Human, Safety, Pharma, MRK, Addiction, SNAC, AstraZeneca, PFE, DKK, Blood, Mouth, Novo Nordisk, Vomiting, Autoimmune disease, Research, Diarrhea, Weight loss, Hanmi Pharmaceutical, Weapon, Clinical trial, Refrigeration, Chronic kidney disease, Growth, Pharmaceutical industry

NEW YORK, Jan. 8, 2024 /PRNewswire/ -- Already proven to be a revolutionary treatment for type 2 diabetes and weight loss, glucagon-like peptide-1 (GLP-1) agonists now appear to have a multitude of potential blockbuster therapeutic uses, according to recent research. Obviously, diabetes remains a primary indication, given the massive global need. However, the impact of this extraordinary molecule extends far beyond type 2 diabetes. The reach of GLP-1 drugs has widened in ways its inventors likely never imagined. Clinical trials are underway testing GLP-1 drugs to treat Alzheimer's, Parkinson's, and even drug addiction, plus there are strong indications of therapeutic efficacy in heart disease and chronic kidney disease, as well as a wide range of other conditions, including weight loss. The newfound applications of this super-drug re-enforce both the reach and impact of Lexaria Bioscience Corp. (NASDAQ: LEXX) (Profile). By supercharging GLP-1 drugs with its DehydraTECH(TM) drug-delivery formulation and processing technology, Lexaria intends to improve both delivery and efficacy of GLP-1 for diabetes and potentially a host of other maladies. With several key studies on the near-term horizon, Lexaria has positioned itself in the midst of these market opportunities alongside others changing the landscape, such as Pfizer Inc. (NYSE: PFE), Merck & Company Inc. (NYSE: MRK), AstraZeneca PLC (NASDAQ: AZN) and Novo Nordisk (NYSE: NVO).

Key Points: 
  • GLP-1 agonists are the hottest drugs in healthcare today, with uses targeting multibillion-dollar diabetes and obesity markets and much more.
  • Similarly, product sales for obesity drugs are forecast to reach $100 billion within a decade, and the most promising drugs at the head of the pack are GLP-1 agonists.
  • Novo Nordisk (NYSE: NVO) , the owner of Ozempic(R), Rybelsus(R), Victoza(R) and Wegovy(R), is a world leader in diabetes and GLP-1 drugs.
  • Companies that enhance efficacy and expand usage could prove to be the biggest winners in the progression of GLP-1 drugs.

Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs

Retrieved on: 
Monday, January 8, 2024
Editorial, Diabetes, Risk, CER, Fatty liver disease, Health, Nausea, Tissue, Heart, Cancer, Inflammation, Patent, Ageing, Obesity, Crohn's disease, Liver disease, LEXX, NVO, Invention, DSM-IV codes, Parkinson's disease, Pfizer, Kidney disease, Paratriathlon, European, Disease, Alzheimer's disease, Pharmacokinetics, Bone density, Merck, Facial muscles, Human, Safety, Pharma, MRK, Addiction, SNAC, AstraZeneca, PFE, DKK, Blood, Mouth, Novo Nordisk, Vomiting, Autoimmune disease, Research, Diarrhea, Weight loss, Hanmi Pharmaceutical, Weapon, Clinical trial, Refrigeration, Chronic kidney disease, Growth, Pharmaceutical industry

NEW YORK, Jan. 8, 2024 /PRNewswire/ -- Already proven to be a revolutionary treatment for type 2 diabetes and weight loss, glucagon-like peptide-1 (GLP-1) agonists now appear to have a multitude of potential blockbuster therapeutic uses, according to recent research. Obviously, diabetes remains a primary indication, given the massive global need. However, the impact of this extraordinary molecule extends far beyond type 2 diabetes. The reach of GLP-1 drugs has widened in ways its inventors likely never imagined. Clinical trials are underway testing GLP-1 drugs to treat Alzheimer's, Parkinson's, and even drug addiction, plus there are strong indications of therapeutic efficacy in heart disease and chronic kidney disease, as well as a wide range of other conditions, including weight loss. The newfound applications of this super-drug re-enforce both the reach and impact of Lexaria Bioscience Corp. (NASDAQ: LEXX) (Profile). By supercharging GLP-1 drugs with its DehydraTECH(TM) drug-delivery formulation and processing technology, Lexaria intends to improve both delivery and efficacy of GLP-1 for diabetes and potentially a host of other maladies. With several key studies on the near-term horizon, Lexaria has positioned itself in the midst of these market opportunities alongside others changing the landscape, such as Pfizer Inc. (NYSE: PFE), Merck & Company Inc. (NYSE: MRK), AstraZeneca PLC (NASDAQ: AZN) and Novo Nordisk (NYSE: NVO).

Key Points: 
  • GLP-1 agonists are the hottest drugs in healthcare today, with uses targeting multibillion-dollar diabetes and obesity markets and much more.
  • Similarly, product sales for obesity drugs are forecast to reach $100 billion within a decade, and the most promising drugs at the head of the pack are GLP-1 agonists.
  • Novo Nordisk (NYSE: NVO) , the owner of Ozempic(R), Rybelsus(R), Victoza(R) and Wegovy(R), is a world leader in diabetes and GLP-1 drugs.
  • Companies that enhance efficacy and expand usage could prove to be the biggest winners in the progression of GLP-1 drugs.

Boston Pharmaceuticals Presents Data at NASH-TAG 2024 Demonstrating Low Immunogenicity Over Time With Long-acting FGF21 Analogue, BOS-580, for MASH

Retrieved on: 
Friday, January 5, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, NAFLD, Risk, ADAS, NASH, Division, Hepatology, Non-alcoholic fatty liver disease, ADAPT, CMO, Prevalence, University of California, Medication, Liver injury, University, Fatty liver disease, MASH, Biomarker, FAST, FGF21, Patient, Fibrosis, Therapy, Aspartic acid

The data were presented at NASH-TAG 2024 (Jan. 4-6, 2024) in Park City, Utah.

Key Points: 
  • The data were presented at NASH-TAG 2024 (Jan. 4-6, 2024) in Park City, Utah.
  • “This low immunogenicity distinguishes BOS-580 from other FGF21 analogues currently in development.”
    Another analysis of data from Boston Pharmaceuticals’ Phase 2a trial demonstrated the impact of BOS-580 treatment on several non-invasive indicators of fibrosis based on markers of liver injury and fibrosis in MASH patients.
  • “Our latest data highlight that BOS-580 has great potential to become a backbone in the treatment of patients suffering from MASH.
  • We believe BOS-580 may offer a compelling and convenient treatment option for people living with MASH,” said Juan Carlos Lopez-Talavera, M.D., Ph.D., CMO of Boston Pharmaceuticals.

Madrigal Pharmaceuticals Presents Five Health Economics Outcomes Research Abstracts at the NASH-TAG Annual Conference

Retrieved on: 
Thursday, January 4, 2024
Database, Conference, Elastography, Risk, Registry, NASH, Biopsy, Fatty liver disease, Research, Disease, Health, Cirrhosis, Abstract, MASH, FAST, Patient, Therapy, Fibrosis, Medical imaging

Jesse Fishman, Senior Director, Health Economics and Outcomes Research at Madrigal, stated, “We are gaining important new insights about the serious risks and complications associated with uncontrolled NASH through analyses of real-world data from patient registries and health system databases.

Key Points: 
  • Jesse Fishman, Senior Director, Health Economics and Outcomes Research at Madrigal, stated, “We are gaining important new insights about the serious risks and complications associated with uncontrolled NASH through analyses of real-world data from patient registries and health system databases.
  • The serious burden of uncontrolled NASH on patients and the health system is coming into focus: as the disease progresses to cirrhosis, patients face markedly elevated risk of liver-related and cardiovascular outcomes.
  • Among patients with cirrhosis, ≥25% were not seen by a specialist at the recommended frequency of once per year.
  • This finding underscores the necessity of revisiting current cardiovascular risk models for patients with NASH to incorporate more holistic and liver-specific variables.

Hepion Pharmaceuticals to Present at NASH-TAG 2024

Retrieved on: 
Wednesday, January 3, 2024
Artificial intelligence, Conference, HEPA, Fatty liver disease, Conditional sentence, Treatment

EDISON, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, hepatocellular carcinoma (“HCC”), and other chronic diseases, today announced that an abstract highlighting its lead drug candidate, rencofilstat, will be presented at the 2024 NASH-TAG Conference, which is being held January 4-6, 2024, in Park City, Utah.

Key Points: 
  • EDISON, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, hepatocellular carcinoma (“HCC”), and other chronic diseases, today announced that an abstract highlighting its lead drug candidate, rencofilstat, will be presented at the 2024 NASH-TAG Conference, which is being held January 4-6, 2024, in Park City, Utah.
  • Title: Hepatic Functional Improvement Detected by HepQuant DuO within 120 Days of Treatment with Rencofilstat in MASH Subjects with ≥F3 Fibrosis.
  • A copy of the presentation materials will be accessible on the Company’s website at www.hepionpharma.com under “Publications” in the Pipeline section.